
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma is a clinical-stage pharmaceutical company with a focus on developing cannabinoid-based therapies for treating Alzheimer's disease, a growing market with significant unmet needs. The company's strong performance in patient enrollment and its reported positive interim results for its Phase 2 trial of IGC-AD1 demonstrate its potential to successfully address the symptoms of Alzheimer's disease. Despite the risks involved, the current valuation appears to be attractive and the ongoing progress and potential for growth make it a promising investment opportunity.
Bears say
IGC Pharma is a medical cannabis based company that shows potential in treating conditions such as Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. However, with the company's minimal revenue generation and lack of Q3 guidance, it is concerning that its upcoming milestones in mid-2026 may not materialize as expected. Furthermore, the company's decision to change its fiscal year end and focus solely on Alzheimer's disease may limit its potential in exploring other medical conditions, making it a risky investment choice.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares